SmithMidland (SMID)
(Delayed Data from NSDQ)
$35.81 USD
+4.33 (13.75%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $35.87 +0.06 (0.17%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$35.81 USD
+4.33 (13.75%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $35.87 +0.06 (0.17%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Smith-Midland (SMID) Earnings & Revenues Rise Y/Y in Q2
by Zacks Equity Research
Increased production and higher sales volumes across multiple product lines aid Smith-Midland's (SMID) earnings in Q2.
ASML and Malibu Boats have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
ASML and Malibu Boats have been highlighted as Zacks Bull and Bear of the Day.
3 Microcaps to Benefit from Federal Highway Spending
by Mark Zinski
The IIJA (Infrastructure Investment and Jobs Act) is a $1.2 trillion investment over a five-year period.
Zacks Initiates Coverage of Smith-Midland With Neutral Recommendation
by Urbashi Dutta
Discover why Zacks rates Smith-Midland (SMID) as "Neutral," being the first on Wall Street to initiate the coverage of the stock. Explore SMID's robust revenue growth and operational improvements amid significant risks, including rising material costs and dependency on a single customer.
The Zacks Analyst Blog Highlights Abbott Laboratories, BP, Gilead Sciences, Smith-Midland and Crimson Wine
by Zacks Equity Research
Abbott Laboratories, BP, Gilead Sciences, Smith-Midland and Crimson Wine are included in this Analyst Blog.
Top Analyst Reports for Abbott, BP & Gilead
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Abbott Laboratories (ABT), BP p.l.c. (BP) and Gilead Sciences, Inc. (GILD), as well as two micro-cap stocks Smith-Midland Corporation (SMID) and Crimson Wine Group, Ltd. (CWGL).